• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Liquidia Corporation

    1/16/24 7:42:57 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    SC 13G 1 d590854dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Liquidia Corporation

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    53635D202

    (CUSIP Number)

    January 4, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 53635D202       Page 1 of 5 Pages

     

      1    

      NAME OF REPORTING PERSON

     

      Legend Aggregator, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      7,182,532

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      7,182,532

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,182,532

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.5% (1)

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      PN

     

    (1)

    Based upon 75,812,107 shares of Common Stock, which is the sum of (i) 68,629,575 shares of Common Stock issued and outstanding as of December 31, 2023 according to information provided in writing by the Issuer to the Reporting Persons and (ii) 7,182,532 shares of Common Stock issued to Legend Aggregator, LP in connection with a private offering of Common Stock.


    CUSIP No. 53635D202       Page 2 of 5 Pages

     

      1    

      NAME OF REPORTING PERSON

     

      Legend Aggregator Advisors, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      7,182,532

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      7,182,532

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      7,182,532

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      9.5% (1)

    12  

      TYPE OF REPORTING PERSON (See Instructions)

     

      OO

     

    (1)

    Based upon 75,812,107 shares of Common Stock, which is the sum of (i) 68,629,575 shares of Common Stock issued and outstanding as of December 31, 2023 according to information provided in writing by the Issuer to the Reporting Persons and (ii) 7,182,532 shares of Common Stock issued to Legend Aggregator, LP in connection with a private offering of Common Stock.


    CUSIP No. 53635D202       Page 3 of 5 Pages

     

    Item 1(a). Name of Issuer

    Liquidia Corporation (the “Issuer”)

    Item 1(b). Address of Issuer’s Principal Executive Offices

    419 Davis Drive, Suite 100

    Morrisville, North Carolina 27560

    Item 2(a). Name of Person Filing.

    This Statement is being filed jointly by each of Legend Aggregator, LP, a Delaware limited partnership, and Legend Aggregator Advisors, LLC, a Delaware limited liability company (collectively with Legend Aggregator, LP, the “Reporting Persons”). Legend Aggregator Advisors, LLC is the general partner of Legend Aggregator, LP. Voting and investment power over the shares held by the Reporting Persons is exercised by a three-member management committee of Legend Aggregator Advisors, LLC, and pursuant to the governing documents of Legend Aggregator Advisors, LLC, voting and disposition decisions require the approval of a majority of such persons.

    Item 2(b). Address or Principal Business Office, or if none, Residence

    The principal business address of each of the Reporting Persons is 2884 Sand Hill Road, Suite 100, Menlo Park, CA 94025.

    Item 2(c). Citizenship

    Please refer to Item 4 on each cover page for each Reporting Person.

    Item 2(d). Title of Class of Securities

    Common Stock, par value $0.001 per share

    Item 2(e). CUSIP Number

    53635D202

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

    Not applicable.

    Item 4. Ownership

     

      (a)

    Amount Beneficially Owned:

    See response to Item 9 on each cover page.

     

      (b)

    Percent of Class:

    See response to Item 11 on each cover page.

     

      (c)

    Number of Shares as to which the Reporting Person has:

     

      (i)

    Sole Power to Vote or Direct the Vote:

    See response to Item 5 on each cover page.


    CUSIP No. 53635D202       Page 4 of 5 Pages

     

      (ii)

    Shared Power to Vote or to Direct the Vote:

    See response to Item 6 on each cover page.

     

      (iii)

    Sole Power to Dispose or to Direct the Disposition of:

    See response to Item 7 on each cover page.

     

      (iv)

    Shared Power to Dispose or Direct the Disposition of:

    See response to Item 8 on each cover page.

    Item 5. Ownership of Five Percent or Less of a Class

    If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group

    Not Applicable.

    Item 10. Certification

    By signing below, each of the Reporting Persons certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 53635D202       Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: January 16, 2024     LEGEND AGGREGATOR, LP
        By:  

    Legend Aggregator Advisors, LLC

    Its: General Partner

        By:   /s/ Adam Fliss
          Name: Adam Fliss
          Title: Vice President
        LEGEND AGGREGATOR ADVISORS, LLC
        By:   /s/ Adam Fliss
          Name: Adam Fliss
          Title: Vice President


    EXHIBIT LIST

     

    Exhibit A    Joint Filing Agreement, dated as of January 16, 2024

     

    Get the next $LQDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    9/19/2022$3.00Underperform
    Wedbush
    9/1/2022$3.00Neutral → Underperform
    Wedbush
    More analyst ratings

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Adair Jason sold $6,479 worth of shares (455 units at $14.24), decreasing direct ownership by 0.25% to 183,849 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/30/25 4:15:23 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Saggar Rajeev sold $33,492 worth of shares (2,450 units at $13.67), decreasing direct ownership by 0.92% to 263,152 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/23/25 4:15:13 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Schundler Russell sold $80,931 worth of shares (5,964 units at $13.57), decreasing direct ownership by 1% to 570,301 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:06:09 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will

      5/8/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

      MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company's Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-pre

      5/6/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

      Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia's amendment to its New Drug Application (NDA) for YUTREPIA™ (t

      5/2/25 5:28:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      11/12/24 5:35:19 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/12/24 4:22:57 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/4/24 5:51:42 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

      Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

      11/18/21 2:49:33 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Liquidia Corporation

      10-Q - Liquidia Corp (0001819576) (Filer)

      5/8/25 7:00:23 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:40:47 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:05:36 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

      GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

      10/2/23 7:00:00 AM ET
      $EBS
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

      7/21/22 4:30:00 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/16/24 4:05:20 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/4/24 5:51:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/18/23 5:02:01 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Financials

    Live finance-specific insights

    See more
    • Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

      MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

      5/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

      MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora

      11/4/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

      MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

      7/31/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Liquidia Technologies with a new price target

      Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

      12/20/24 7:42:58 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Liquidia Technologies

      Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Technologies upgraded by Raymond James

      Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy

      8/19/24 12:03:58 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care